Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Strategies Following Local Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
ChiCTR2500112624Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tislelizumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500112624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112624.